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Abstract
Background: Death adders (Acanthophis spp) are found in Australia, Papua New Guinea and parts of eastern Indonesia. This
study aimed to investigate the clinical syndrome of death adder envenoming and response to antivenom treatment.
Methodology/Principal Findings: Definite death adder bites were recruited from the Australian Snakebite Project (ASP) as
defined by expert identification or detection of death adder venom in blood. Clinical effects and laboratory results were
collected prospectively, including the time course of neurotoxicity and response to treatment. Enzyme immunoassay was
used to measure venom concentrations. Twenty nine patients had definite death adder bites; median age 45 yr (5–74 yr); 25
were male. Envenoming occurred in 14 patients. Two further patients had allergic reactions without envenoming, both
snake handlers with previous death adder bites. Of 14 envenomed patients, 12 developed neurotoxicity characterised by
ptosis (12), diplopia (9), bulbar weakness (7), intercostal muscle weakness (2) and limb weakness (2). Intubation and
mechanical ventilation were required for two patients for 17 and 83 hours. The median time to onset of neurotoxicity was
4 hours (0.5–15.5 hr). One patient bitten by a northern death adder developed myotoxicity and one patient only developed
systemic symptoms without neurotoxicity. No patient developed venom induced consumption coagulopathy. Antivenom
was administered to 13 patients, all receiving one vial initially. The median time for resolution of neurotoxicity post-
antivenom was 21 hours (5–168). The median peak venom concentration in 13 envenomed patients with blood samples
was 22 ng/mL (4.4–245 ng/mL). In eight patients where post-antivenom bloods were available, no venom was detected
after one vial of antivenom.
Conclusions/Significance: Death adder envenoming is characterised by neurotoxicity, which is mild in most cases. One vial
of death adder antivenom was sufficient to bind all circulating venom. The persistent neurological effects despite
antivenom, suggests that neurotoxicity is not reversed by antivenom.
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Introduction
Death adders (genus Acanthophis) are a member of the snake
family Elapidae. They inhabit most of Australia (excluding
Victoria and Tasmania), Papua New Guinea, Irian Jaya and
the Indonesian islands of Seram, Halmahera, Obi and
Tanimbar. Considerable debate about the taxonomy of
individual species continues, with up to 12 species of death
adder being proposed [1,2]. Death adders are readily
distinguishable from other Australian snakes by their ‘‘viper-
like’’ appearance. They also differ to other Australian elapids
because they are ambush predators, being primarily active at
night.
Death adder venom has been the subject of considerable in vitro
investigation and several venom components have been isolated
and identified. Until recently, post-synaptic neurotoxins were
thought to be the most important components of death adder
venom and numerous post-synaptic toxins have been isolated [2–
6]. However, recent work has identified a number of pre-synaptic
neurotoxins present in at least three species of death adder [7–9].
Several other components have been identified in death adder
venom, including myotoxins, pro-coagulants, anticoagulants and
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toxins which interfere with platelet aggregation [10–17]. The
clinical significance of several of these components remains
unclear.
There is limited published information about the clinical effects of
death adder envenoming and its treatment. Neurotoxicity appears
to be the most important clinical effect of death adder envenoming
[2,18,19]. Most of the available clinical information comes from two
case series from Port Moresby General Hospital in Papua New
Guinea. Campbell’s 1966 paper provided the first case series of
death adder bites with 15 cases [18]. It included five patients with
evidence of neurotoxicity, two of whom had extensive paralysis. The
study describes the successful reversal of envenoming with
antivenom therapy but does not provide objective evidence of the
duration of effects after treatment. Definite identification of the
involved snake was only available for some of the cases. Lalloo et al
reported a further 32 cases of death adder bites from Papua New
Guinea with confirmation by enzyme immunoassay [19]. Neuro-
toxicity was a feature in 17 (53%) of these patients, with five patients
requiring intubation and ventilation. The study found a variable
response to antivenom, with some cases responding rapidly with a
reversal of effects, and other cases not responding at all.
The limited information on Australian death adder bites does
not provide a complete description of the envenoming syndrome.
In a prospective series of 21 cases from tropical northern Australia,
eight (38%) developed neurotoxicity [20]. There is controversy
regarding the dose and effectiveness of antivenom and whether
adjunctive therapy with anticholinesterases such as neostigmine
play a role in treatment [2,20–27]. The aim of this study is to
describe the clinical syndrome of death adder envenoming in
Australia and evaluate the response of death adder envenoming to
antivenom therapy.
Methods
The study is a prospective cohort study of definite death adder
(Acanthophis spp) bites recruited to the Australian Snakebite Project
(ASP).
Materials
Acanthophis antarcticus (Common Death Adder) venom was
purchased from Venom Supplies, South Australia. Death adder
antivenom was manufactured by CSL Ltd. Polyclonal monovalent
rabbit IgG to A. antarcticus venom was purchased from the Western
Australian Institute for Medical Research. Tetramethylbenzidine
(TMB) was purchased from Sigma. Rabbit IgG was biotinylated
using EZ-link sulfo-NHS-LC-Biotin (Pierce #21335). Streptavi-
din-conjugated horseradish peroxidise was purchased from Milli-
pore Chemicon. Skim milk ‘Diploma’ brand instant powder was
prepared as a 1% solution in phosphate buffered saline (PBS) for
blocking solution. Bovine Serum Albumin (BSA) was obtained
from Bovostar. Greiner microlon high binding 96 well plates were
used for the enzyme immunoassays. The plates were read on a
BioTek ELx808 at 450 nm.
Patients and Patient samples
Patients with death adder bites were recruited as part of the
Australian Snakebite Project (ASP). ASP is an ongoing prospective
multicentre study which recruits patients from over 100 hospitals
in Australia. The inclusion criterion for ASP is any patient who has
been bitten by a snake, either suspected or confirmed. The only
exclusion criterion is any patient less than two years of age.
Patients are recruited to the ASP by local investigators present in
treating or referral hospitals, or by clinical toxicologists when
contact is made through the Poisons Information Centre Network
in Australia. Patient information, patient consent, study proce-
dures and datasheets are faxed to local investigators and are
included as Protocol S1. Ethics approval has been obtained from
the human research ethics committee of the Menzies School of
Health Research and 20 human research ethics committees
relevant to all institutions involved in the study. Informed written
consent was obtained from all patients in the study.
Information on patient demographics, bite circumstances,
clinical evaluation of the patient, laboratory results, treatments
given and response to therapy are recorded for all patients
recruited on datasheets made available to treating doctors. All
decisions about treatment of the patient are made by the treating
doctor or from advice given by the National Poison Information
Centre Network. This information is entered in the study database
and coded to a clinical envenoming syndrome according to
previously defined criteria [28].
Multiple serum samples are taken from each patient both pre-
and post-antivenom administration which are then spun, ali-
quotted and stored at 280uC for later analysis of venom and
antivenom. The pre-antivenom samples are used to confirm the
presence and concentration of specific venoms. Post-antivenom
samples are used to confirm the absence of detectable free venom
after antivenom administration.
The ASP database was searched from January 2002 to January
2012 for all potential cases of death adder bites. Potential death
adder bite cases were defined by either a positive CSL snake
venom detection kit (sVDK) result, expert identification of the
snake or by clinical findings that were suggestive of envenoming by
death adder (eg. neurotoxicity in the absence of coagulopathy).
Blood samples from these possible cases were analysed to confirm
the type of venom with enzyme immunoassay if pre-antivenom
blood was available. Definite cases were defined as those with
positive expert identification or detection of death adder venom
with specific venom enzyme immunoassay.
Enzyme Immunoassay
Specific venom enzyme immunoassay was performed on all
patient samples using a previously described technique developed
for Australian snakebites [29]. All washings were done with 0.02%
Tween 20 in PBS. Plates were coated with 100 mL of rabbit anti-
A.antarcticus IgG 1 mg/mL in carbonate buffer (50 mM pH 9.6).
Author Summary
Death adders are a genus of venomous snakes found in
Australia, Papua New Guinea and Indonesia. Death adder
envenoming is a rare but important health problem in
Australasia. Definite death adder bites were recruited as
part of the Australian Snakebite Project (ASP). Clinical
effects, laboratory results and response to antivenom
treatment were recorded for each case. Death adder
envenoming was confirmed by enzyme immunoassay in
blood collected from patients. The most important clinical
effect was neurotoxicity, which was mild in most cases.
One vial of antivenom was shown to be effective at
binding circulating death adder venom. However, anti-
venom had little effect on the neurotoxicity that devel-
oped in envenomed patients and neurotoxicity took on
average one day to resolve. This study supports the idea of
presynaptic neurotoxicity in death adder envenoming
which was previously thought to be due to post-synaptic
neurotoxicity. The study calls into question the benefit of
antivenom, with poor response shown in patients with
both mild and severe envenoming.
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After one hour at room temperature they were refrigerated at 4uC
overnight. Each plate was washed and then blocked with 300 mL
of blocking solution (dilute skim milk) to occupy free binding sites
on the plates. Each plate was then washed again after one hour
before adding 100 mL of patient sample, control or spiked sample
to each well, as a dilution of 10% or 1% or both, in PBS.
Following three washes, 100 mL of biotinylated rabbit anti-
A.antarcticus IgG (0.2 ug/mL in 0.5% BSA/PBS) was added to
each sample. After a further hour the plates were washed another
three times, and 100 mL of Strepavidin-conjugated horseradish
peroxidase (0.15 mg/mL in 0.5% BSA/PBS) was added. Then,
after 1 hour the plates were again washed three times. Tetra-
methylbenzidine (100 mL) was added and the colour left to develop
for two minutes. Then to each sample 50 mL of 1M sulfuric acid
was added to halt the reaction. Samples are all performed in
triplicate and the mean value calculated. The coefficient of
variation was less than 5% for all experiments.
Level of detection/level of blank determination
The EP17-A protocol was used to determine the limit of blank
and limit of detection of the assay [30]. Previous studies of taipan
(Oxyuranus sp.) venom have shown that using this approach the
level of detection can be set as low as 0.15 ng/mL [29]. Twenty
four non-envenomed serum samples were measured unspiked
(blank) and spiked at a concentration such that the overlap of
absorbance with the unspiked samples was #5%. This level was
determined as 0.2 ng/ml.
Data Analysis
Standard curves were fitted by linear and non-linear regression
and the data was plotted to fit a sigmoidal dose–response curve
with an r2 value of 0.99. Normality of the data was assessed by the
Kolmogorov-Smirnov test and the Shapiro-Wilk normality test.
Descriptive data is presented as medians with interquartile ranges
(IQR) and ranges. All analyses and graphics were done in
GraphPad Prism version 5.03 for Windows, GraphPad Software,
San Diego California USA, www.graphpad.com.
Results
From 35 potential cases identified, six were excluded because
they did not have expert identification of the snake or venom
detected by enzyme immunoassay. The 29 definite death adder
bites are summarised in Table 1.
Demographic and bite circumstance data
The median age of the patients was 45 years (IQR: 33–52 y;
Range 5–74 y,); 25 patients were male (86%). The bite site was the
upper limb in 20 cases (69%), lower limb in eight cases (28%) and
not known in one case. The activity that led to the bite was
intentionally interfering with the snake in 17 cases (59%), stepping
on or near the snake in seven cases (24%), removing debris or
interfering with something on the ground near the snake in four
cases (14%) and not known in one case. Bites to snake handlers
made up 15 of the cases (52%). Adequate pressure bandage with
immobilisation was used as first aid in 22 cases (76%). Of the 14
death adder bites that occurred in the wild, nine of them occurred
in the evening/night between 6pm and 6am.
The snake was identified as a death adder by an expert in 19
cases. In nine of these the species of death adder was determined:
four A. praelongus (Northern Death Adder), two A. antarcticus
(Common Death Adder), two A. hawkei (Barkly Tableland Death
Adder) and one A. rugosus (Rough-scaled Death Adder). There
were too few envenomed cases by each species to allow any
comparison between species. Bites occurred all around Australia,
but bites in the wild occurred mainly in the north (Figure 1).
Clinical Effects
Local and regional bite site effects occurred in 20 of the 29
patients which was most commonly pain at the bite site, but in 13
patients there were more severe effects with swelling (11) and
bruising (4) (Figure 2). Over a period of days four patients went on
to develop cellulitis at the bite site requiring antibiotic therapy.
One of these patients required surgery for flexor sheath synovitis
and one required a 48 hour intensive care unit admission for septic
shock following cellulitis at the bite site.
Fourteen of the definite death adder bites resulted in systemic
envenoming (Table 2). Neurotoxicity was the most common
clinical syndrome, with myotoxicity in one patient and no patients
with VICC. In addition to envenoming, two patients had allergic
reactions to venom. There were no deaths. All patients with
systemic envenoming developed local effects except two where
there was no documentation of local effects.
Neurotoxicity developed in 12 patients. In ten patients
neurotoxicity was mild with paralysis limited to muscles innervated
by the cranial nerves and not requiring intubation - ptosis, external
ophthalmoplegia and/or diplopia, and bulbar weakness. The most
common earliest indicator of neurotoxicity was ptosis in 10
patients and then ophthalmoplegia/diplopia in six. The only
patient where the onset of neurotoxicity was observed more than
12 hours post bite at 15.5 hours was a five year old boy who was
not woken overnight to test for ptosis. Severe neurotoxicity
occurred in two patients who required intubation and mechanical
ventilation for 17 and 83 hours. Table 3 provides the time of onset
and resolution of neurotoxicity.
Non-specific systemic symptoms occurred in three patients, one in
which neurotoxicity did not develop. The commonest systemic
Table 1. Characteristics and demographic features of 29
patients with definite death adder bites.
Age [yr]; median (IQR, Range) 45 (33–52; 5–74)
Sex (Male) 25 86%
State/Territory
Northern Territory 8 28%
Queensland 8 28%
New South Wales 6 21%
Western Australia 4 14%
Victoria 3 10%
Bite site1
Upper Limb 20 69%
Lower Limb 8 28%
Circumstances of bite1
Intentionally interfering with snake 17 59%
Stepped on/near snake 7 24%
Clearing debris/activity near snake 4 14%
PBI in place on arrival 22 76%
Antivenom given 13 45%
Snake Handler 15 52%
PBI – pressure bandage with immobilisation.
1In one non-envenomed patient no bite site or circumstances of bite were
recorded.
doi:10.1371/journal.pntd.0001841.t001
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symptoms were nausea and vomiting. Myotoxicity occurred in one
patient bitten by a northern death adder (A. praelongus) who developed
severe local myalgia with a maximum CK of 4770 U/L [31]
Two patients who had previously been bitten by death adders
developed allergic reactions to venom without evidence of
envenoming. The first patient had shortness of breath, erythema
and itch to the affected arm. The second developed widespread
rash, diaphoresis, urinary and faecal incontinence, and tongue/
peri-orbital oedema.
Laboratory investigations
Laboratory investigation results were available for 12 of the 14
systemically envenomed patients. All 12 patients an elevated white
cell count, with a median peak value of 17.56109 (Range 11.4–
41.96109) and an elevated neutrophil count, with a median value
of 15.56109 (range 10.4–39.36109). Lymphocyte count was
decreased in all 12 patients with a median nadir value of
0.96109 (Range 0.3–1.36109). The activated partial thrombo-
plastin time (aPTT) was elevated in two envenomed patients (45
and 49 sec) who had normal fibrinogen levels. A bite site sVDK
was performed in eight of the 14 envenomed cases, which were all
positive for death adder. In a further three of the 14 a urine sVDK
was done and all three were positive for death adder venom.
Treatment
Antivenom was administered to all 12 patients with evidence of
neurotoxicity and to the patient with myotoxicity. All patients
received CSL monovalent death adder antivenom and an initial
dose of one vial of antivenom. Subsequent doses of antivenom
were administered to eight of the patients. The median dose of
antivenom administered was 2 vials (Range 1–5) and the median
time from bite to antivenom was 10 hours (IQR: 5–15 hr).
The median time of resolution of all features of neurotoxicity
after antivenom therapy was 21 hours (IQR 5.0–28.5 hr; Range
5–168 hr). The early use of antivenom did not appear to be
associated with less severe neurotoxicity. In the two patients with
increased aPTT results, the aPTT returned to the normal range
rapidly after these patients received antivenom.
Systemic hypersensitivity reactions occurred in five patients
receiving antivenom. These were mild (limited to the skin) in four
cases however one anaphylactic reaction occurred with urticaria,
wheeze, dyspnoea and chest tightness. Antivenom was not stopped
in any patients because of these reactions.
Neostigmine was administered to four patients including the two
patients with severe neurotoxicity requiring intubation. In the first
intubated patient, a dose of 2.5 mg of neostigmine was given with
600 mcg of atropine after intubation. Although the ptosis
appeared to resolve the patient had ongoing respiratory weakness
requiring intubation for a further five hours. The second intubated
patient received three boluses of 0.5 mg, 2.5 mg and 2.5 mg of
neostigmine followed by an infusion of 20 mcg per hour for
24 hours. After an initial improvement with eye opening, no
further improvement in neurotoxicity was observed and the
infusion was ceased due to bradycardia. Two other patients
Figure 1. Geographical location of death adder bites, including bites by captive snakes (red star) and bites by snakes in the wild
(yellow circle).
doi:10.1371/journal.pntd.0001841.g001
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Figure 2. Local effects from a death adder bite to the foot.
doi:10.1371/journal.pntd.0001841.g002
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received neostigmine and atropine therapy with no demonstrated
clinical benefit.
Venom immunoassays
Pre-antivenom blood samples were available for 10 of the 12
patients with neurotoxicity and the one patient who had non-
specific systemic effects in isolation. The median peak venom
concentration was 22 ng/mL (IQR: 8.5–29 ng/mL, range 4.4–
245 ng/mL). The patient who developed myotoxicity had no
detectable venom in his pre-antivenom blood sample but that
sample had measurable human IgG against death adder venom,
consistent with his previous death adder bite. Death adder venom
was detected in blood samples from four patients who did not have
evidence of systemic envenoming, with concentrations of 0.7, 0.9,
3.7 and 40 ng/mL.
In the eight cases where post-antivenom blood samples were
available, including the patient with the highest venom level of
245 ng/mL, there was no detectable venom. All of these patients
had only received their first vial of death adder antivenom before
this blood sample was taken.
Discussion
This study confirms that neurotoxicity is the main feature of
envenoming by Australian death adders and that in the majority of
cases severe life-threatening paralysis does not develop. Measure-
ment of venom concentrations demonstrated that all free venom
was bound after one vial of death adder antivenom so larger doses
are not required. This included patients envenomed by four
different death adder species. Neurotoxicity did not appear to
resolve or reverse with the use of antivenom. Previously reported
possible effectiveness of anticholinesterates [27,32–34] was not
supported by this study, with the use of neostigmine providing little
benefit in four cases. Given that neurotoxicity did not appear to
resolve or reverse with the use of antivenom or anticholinesterases
it is most likely to be due to irreversible injury from presynaptic
neurotoxins, similar to the neurotoxicity from other Australian
elapids such as the taipan [2,35]. Although it is possible that
antivenom prevented those with mild neurotoxicity from getting
progressively worse, this only occurred in one patient (Table 3,
Row 4) and the two patients with severe neurotoxicity received
antivenom within 6 hours (Table 3).
The current recommended guidelines for snake bite patients in
Australia of observation for at least 12 hours and not discharging
at night, are well supported by the data in the study. Only one
patient had delayed onset of neurotoxicity (15.5 hours), and it is
likely that earlier onset was not picked up due to limited
observations overnight, particularly waking this child to assess
ptosis. A previous analysis of ASP data showed that all cases of
neurotoxicity developed within 12 hours [36].
Just over half of death adder bites were in snake handlers which
is the reason that a number of bites occurred in regions where
death adders do not occur in the wild, such as Victoria. It also
explains, in part, the reason for the predominance of upper limb
bites, when compared to other studies of Australian snakes [37].
The study supports the fact that death adder bites from snakes in
Table 2. Clinical effects in 14 patients with death adder
envenoming.
Clinical Effects Number
Neurotoxicity 12
Ptosis 12
External ophthalmoplegia/diplopia 9
Bulbar weakness 7
Intercostal weakness 2
Limb weakness 2
Local/regional bite site effects 12
Bite site pain 7
Bite site swelling 7
Regional lymph node pain 7
Bite site bruising 3
Myotoxicity 1
Non-specific systemic effects 3
doi:10.1371/journal.pntd.0001841.t002
Table 3. Summary of patients with neurotoxicity including the time of onset and resolution and the time of antivenom.
Age/Sex Features of Neurotoxicity1 Time to onset Time to antivenom Time to resolution
52/M P,D,B,I,L 0.5 3.25 62
50/M P,D,B,I,L 1 4.25 173
74/M P,D,B 1.5 13 44.5
52/F P 3 4.5 9.5
53/F P,D,B 3.5 8 16.5
54/F P,D,B 4 6.75 26
7/M P,B 4 17.75 23
41/M P,D 5 5.25 32.8
9/M P,D 5.5 42 47
65/M P,D 9.25 14 37
26/M P,D,B 12 12.75 40
5/M P 15.5 18.5 23.5
4.0 hr (IQR: 2.6–6.4 hr) 10 hr (IQR: 5–15 hr) 35 hr (IQR: 24 to 45 hr)
1P - Ptosis, D – Diplopia/External Ophthalmoplegia, B - Bulbar Weakness, I – Intercostal Weakness, L - Limb weakness.
doi:10.1371/journal.pntd.0001841.t003
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the wild are rare. In addition, they are more likely to occur at night
and when the snake is disturbed. Unlike other Australasian elapids
death adders are ambush predators and they are most active
nocturnally.
In this study it has been shown that patients bitten by death
adders have a characteristic pattern of white blood cell count
changes, namely leucocytosis, neutrophilia and lymphopenia. This
has been previously reported for snake envenoming [38], but
because it is less reliable in some snake species such as brown
snakes [36], it is only helpful if the snake is known to be a death
adder. An anticoagulant type coagulopathy was seen in two
patients, an effect that has not been described in Australian death
adder bites before. This is similar to the coagulopathy seen in
Australian black snake bites with an elevation of the aPTT [37]
and although a useful marker of envenoming is unlikely to be
clinically significant. Normal fibrinogen levels confirm that it is not
a consumption coagulopathy.
Low concentrations of death adder venom were detected in
blood samples from three patients who had no signs of systemic
envenoming. These three concentrations were below those of any
of the patients that developed neurotoxicity, indicating that a
threshold blood concentration may need to be reached before
neurotoxicity occurs. There was one patient with a high death
adder venom concentration in their blood sample without any
evidence of envenoming, indicating possible inter-person variabil-
ity in susceptibility to venom effects and/or inter-snake variability
in venom toxin composition [10,39]
Some possible limitations of the study include the method of
selection of cases for examination which in some patients was
based upon prior knowledge of the syndrome of death adder
envenoming. This may mean that some cases of death adder bite
may have been missed and may be the reason for the much higher
incidence of neurotoxicity in our study compared to previous
studies. Because of the rarity of death adder bites and the small
number of some species of death adder included in this study,
other undescribed clinical effects of venom may occur.
This study raises important questions about neurotoxicity,
including the failure of antivenom to reverse neurotoxicity in death
adder bites. This is consistent with the recent isolation of pre-
synaptic neurotoxins in death adder venoms. It supports presyn-
aptic neurotoxicity being the predominant cause of neurotoxicity
in death adder bites as with other neurotoxic Australasian elapids.
This is also consistent with a recent study that has shown that the
rarity of neurotoxicity in brown snake envenoming is due to
presynaptic neurotoxins in brown snake venom being less potent
and only being a small proportion of the venom [40].
Our study suggests that severe neurotoxicity developed early
and rapidly and that early antivenom (within six hours) in these
two patients did not prevent neurotoxicity (Table 3). This differs to
a previous study from Papua New Guinea which found that early
antivenom treatment within 4 hours of a taipan bite was
associated with a lower incidence of intubation/ventilation (33%
compared to 66%) [41]. Conversely, less severe neurotoxicity had
a later onset, and the use of antivenom in these patients also did
not appear to change the natural course of neurotoxicity, except
possibly in one patient (Table 3, Row 4).
The median time to antivenom in the study was 10 hours,
which is much longer than for treating venom induced consump-
tion coagulopathy [42]. Table 3 shows that antivenom was given
in response to the development of neurotoxicity accounting for this
longer time to administration, which also means it is probably
being given too late. It could be argued that antivenom may have
limited benefit in the treatment of death adder neurotoxicity and
that antivenom should only be given early in patients prior to the
rapid onset of neurotoxicity. However, larger and controlled
studies are required to determine this.
Death adder envenoming is rare in Australia but can potentially
cause severe neurotoxicity as seen in two of 14 envenoming cases
in this study. Given the potential for severe neurotoxicity, the
snake’s wide distribution and the presence of the snake in private
collections, it remains an important snake to consider. Whilst most
cases are not life threatening, the failure of antivenom and
anticholinesterases to reverse neurotoxicity once it is established is
a concern. In the absence of a randomised controlled trial
demonstrating the effectiveness of antivenom to prevent the
development of neurotoxicity, and given the demonstrable risk of
giving antivenom (systemic hypersensitivity and anaphylaxis), the
potential benefit of early antivenom remains uncertain.
Supporting Information
Protocol S1 Trial protocol, patient information sheets
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